AU2016341321A1 - Programmable universal cell receptors and methods of using the same - Google Patents

Programmable universal cell receptors and methods of using the same Download PDF

Info

Publication number
AU2016341321A1
AU2016341321A1 AU2016341321A AU2016341321A AU2016341321A1 AU 2016341321 A1 AU2016341321 A1 AU 2016341321A1 AU 2016341321 A AU2016341321 A AU 2016341321A AU 2016341321 A AU2016341321 A AU 2016341321A AU 2016341321 A1 AU2016341321 A1 AU 2016341321A1
Authority
AU
Australia
Prior art keywords
gly
ser
leu
gly gly
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016341321A
Other languages
English (en)
Inventor
Yanwen Fu
Gunnar Jorg Floris Kaufmann
James T. Patterson
Yan-Iiang ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorrento Therapeutics Inc
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of AU2016341321A1 publication Critical patent/AU2016341321A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/15Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4274Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276Prostate specific membrane antigen [PSMA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70517CD8
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002Antibodies with enzymatic activity, e.g. abzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2016341321A 2015-10-23 2016-10-24 Programmable universal cell receptors and methods of using the same Abandoned AU2016341321A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562245978P 2015-10-23 2015-10-23
US62/245,978 2015-10-23
US201662382691P 2016-09-01 2016-09-01
US62/382,691 2016-09-01
PCT/US2016/058429 WO2017070654A1 (en) 2015-10-23 2016-10-24 Programmable universal cell receptors and methods of using the same

Publications (1)

Publication Number Publication Date
AU2016341321A1 true AU2016341321A1 (en) 2018-06-07

Family

ID=58558187

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016341321A Abandoned AU2016341321A1 (en) 2015-10-23 2016-10-24 Programmable universal cell receptors and methods of using the same

Country Status (11)

Country Link
US (1) US20170112878A1 (https=)
EP (1) EP3365016A4 (https=)
JP (1) JP2018537076A (https=)
KR (1) KR20180091820A (https=)
CN (1) CN108883170A (https=)
AU (1) AU2016341321A1 (https=)
CA (1) CA3002774A1 (https=)
EA (1) EA201890941A1 (https=)
TW (1) TW201726914A (https=)
UY (1) UY36961A (https=)
WO (1) WO2017070654A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018537076A (ja) * 2015-10-23 2018-12-20 ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. プログラム可能な普遍的細胞受容体およびその使用法
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US20230159611A1 (en) * 2017-07-03 2023-05-25 Yale University Small molecule adapter regulated, target specific chimeric antigen receptor bearing t cells (smart cars)
CA3080109A1 (en) 2017-11-03 2019-05-09 Sorrento Therapeutics, Inc. Cd38-directed chimeric antigen receptor constructs
AU2019231315A1 (en) * 2018-03-09 2020-09-17 Vivasor, Inc. Dimeric antigen receptors (DAR)
KR20220087519A (ko) * 2019-10-23 2022-06-24 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 촉매 항체 38c2를 위한 신규 접합 화학
EP4114415A1 (en) * 2020-03-06 2023-01-11 Sorrento Therapeutics, Inc. Innate immunity killer cells targeting psma positive tumor cells
CN116601174A (zh) * 2020-10-12 2023-08-15 索伦托药业有限公司 Cd19定向的嵌合抗原受体构建体
KR102618718B1 (ko) * 2021-01-11 2023-12-29 주식회사 유틸렉스 항-4-1bb 항체 및 pd-1 단백질 또는 이의 단편을 포함하는 이중특이적 에피토프 결합 단백질 및 이의 용도
EP4326292A4 (en) * 2021-04-23 2025-03-26 Vivasor, Inc. Dimeric antigen receptors (dars) that bind gd2
US20250186494A1 (en) * 2022-02-10 2025-06-12 The Scripps Research Institute Car-t therapies targeted via covalently bonded adapters

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268488B1 (en) * 1999-05-25 2001-07-31 Barbas, Iii Carlos F. Prodrug activation using catalytic antibodies
US20060235201A1 (en) * 2003-02-06 2006-10-19 Roman Kischel Enduring T cell response
PL2187965T3 (pl) * 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
CA2776143A1 (en) * 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
RU2012157167A (ru) * 2010-07-12 2014-08-20 КовЭкс Текнолоджиз Айэлэнд Лимитед Полифункциональные антительные конъюгаты
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2832540C (en) * 2011-04-08 2020-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
WO2013044225A1 (en) * 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
US10851178B2 (en) * 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
JP2018537076A (ja) * 2015-10-23 2018-12-20 ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. プログラム可能な普遍的細胞受容体およびその使用法

Also Published As

Publication number Publication date
EP3365016A1 (en) 2018-08-29
JP2018537076A (ja) 2018-12-20
WO2017070654A1 (en) 2017-04-27
TW201726914A (zh) 2017-08-01
KR20180091820A (ko) 2018-08-16
EP3365016A4 (en) 2019-07-17
US20170112878A1 (en) 2017-04-27
CA3002774A1 (en) 2017-04-27
UY36961A (es) 2017-05-31
WO2017070654A8 (en) 2017-06-01
EA201890941A1 (ru) 2018-11-30
CN108883170A (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
AU2016341321A1 (en) Programmable universal cell receptors and methods of using the same
JP7642010B2 (ja) 改良された抗原結合受容体
AU2020200751B2 (en) Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
EP3055326B1 (en) Chimeric antigen receptor
JP6549622B2 (ja) 前立腺特異幹細胞抗原に対する抗体およびその使用
CA3090546A1 (en) Chimeric antigen receptors targeting the tumor microenvironment
SA518391219B1 (ar) التركيبات والطرق اللازمة لمجاورة النوع الأول والنوع الثاني من المجالات خارج الخلية كبروتينات كيميرية متغايرة
JP2019533449A (ja) 多量体il−15に基づく分子
KR20180134385A (ko) 선택적 단백질 발현을 위한 조성물 및 방법
JP2015513394A (ja) 二重特異性キメラ抗原受容体およびその治療的使用
CN111712516A (zh) 粘附受体构建体及其在自然杀伤细胞免疫疗法中的用途
US12473343B2 (en) Targeted t cells with cytotoxicity toward immunosuppressive cells
RU2725807C2 (ru) Растворимый универсальный усиливающий adcc синтетический слитный ген, пептидная технология и их применение
US20240352481A1 (en) Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
TW202309091A (zh) 嵌合受體及其使用方法
CN113754778A (zh) 靶向cldn18.2的嵌合抗原受体及其用途
JP2025540340A (ja) キメラ抗原受容体
TW202237633A (zh) 嵌合受體及其使用方法
RU2824391C2 (ru) Иммунные клетки, экспрессирующие обратный универсальный химерный антигенный рецептор, для нацеливания на различные многочисленные антигены и способ их получения и применения для лечения рака, инфекций и аутоиммунных заболеваний
RU2825816C2 (ru) Улучшенные антигенсвязывающие рецепторы
EP4159760A1 (en) Antibody specific to cd22, and use thereof
EP4257608A1 (en) Antibody specific for cd47 and use thereof
WO2023133424A2 (en) Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides
WO2025255266A1 (en) Engineered polypeptides for immune cell activation
WO2025218621A1 (zh) 靶向muc1的抗原结合蛋白

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period